On the basis of these results, PAK4 targeting could enhance the host anti-tumour immunity via T-cells by reducing PD-L1 on tumour cells and activating DCs, especially CD103 + DCs through suppression of the Wnt/β-catenin pathway in OSCC. Here, PAK4 is linked to neoplasm.